Table 1 Patient Characteristics, n = 445
From: 68Ga-PSMA PET/CT in prostate cancer patients – patterns of disease, benign findings and pitfalls
Parameter | Value |
|---|---|
Age | 72.4 years (51–92 years) |
PSA | |
At diagnosis | 46.9 ng/ml (0–4000 ng/ml, median 11.0) |
At time of 68Ga-PSMA PET/CT | 18.4 ng/ml (0.05–533 ng/ml, median 4.3) |
Gleason Score | |
< 6 | 50 (11.4%) |
7 | 128 (29%) |
> 8 | 146 (33%) |
Average | 7.5 |
Therapy prior to 68Ga-PSMA PET/CT | |
Radical Prostatectomy | 150 (34%) |
Radiotherapy/Brachytherapy | 171 (38%) |
Hormonal | 206 (46%) |
Chemotherapy | 23 (5%) |
Other | 27 (6%) |
No prior treatment | 122 (28%) |
Indication for PET/CT | 270(61%) |
Biochemical failure | 112 (25%) |
Staging –high risk | 30 (7%) |
Assess response to treatment | 22 (5%) |
Follow up | 11 (2%) |
Suspected bone metastases | |